Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,664 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Gorham Disease, Lymphatic Diseases, Lymphangiomatosis
Interventions: Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL), Heavy Weighted T2 Imaging (T2W), Lymph Node Access; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions: Stem Cell Transplantation, CD34 selection; Procedure · Device
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Interventions: GW597599; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 17
States / cities: Little Rock, Arkansas • Glendale, California • Laguna Hills, California + 13 more

Conditions: Parkinson Disease
Interventions: HBI-002, Vehicle (placebo); Drug
Lead sponsor: Hillhurst Biopharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Fountain Valley, California • Gainesville, Florida • Boston, Massachusetts + 5 more

Conditions: Autism Spectrum Disorder, Developmental Disability, Aggression, Self-Injurious Behavior, Challenging Behavior
Interventions: Propranolol; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 12 Years to 30 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Rebound Pain, Shoulder Arthroplasty, Interscalene Block
Interventions: Bupivacaine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Rochester, New York

Conditions: Skin Infection, Bacterial Infection
Interventions: Daptomycin, Brilacidin; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 1 more

Conditions: Major Depressive Disorder
Interventions: Low Dose Fish Oil, High Dose Fish Oil; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Septic Shock
Interventions: Angiotensin II; Drug
Lead sponsor: George Washington University; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy
Interventions: Diclofenac Sodium Gel; Drug
Lead sponsor: Amzell; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Advanced Cancer, Metastatic Cancer
Interventions: Q901, KEYTRUDA® (pembrolizumab); Drug
Lead sponsor: Qurient Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more

Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, vincristine sulfate, adjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 35
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 27 more

Conditions: COVID-19
Interventions: GAMUNEX-C, Standard Medical Treatment; Biological · Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 18
States / cities: Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more

Conditions: Chronic Lower Back Pain (CLBP)
Interventions: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions: Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol; Drug · Biological · Radiation + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma, Myeloma
Interventions: FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine, Daratumumab, Bendamustine; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: Birmingham, Alabama • Duarte, California • Denver, Colorado + 11 more

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Palonosetron, ondansetron, Dexamethasone; Drug
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Shigellosis
Interventions: Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 8 Months to 50 Years
Enrollment: 597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 0
States / cities: Not listed

Conditions: Prostate Cancer
Interventions: Pembrolizumab, Olaparib, Androgen Deprivation Therapy, Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: Zin W Myint; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Lexington, Kentucky • Salt Lake City, Utah

Conditions: Myeloid Diseases
Interventions: DFV890; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Stanford, California • Tampa, Florida • Chicago, Illinois + 7 more

Conditions: Gout
Interventions: High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 83
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more

Conditions: HIV Infections
Interventions: HIVAX, saline solution; Biological
Lead sponsor: GeneCure Biotechnologies; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose); Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Melbourne, Florida

Search by objective public record fields.

Imaging of Lymphatic Anomalies

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Propranolol for Challenging Behaviors in Autism

Effect of Local Anesthetic Concentration on Rebound Pain

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Mechanistic Evaluation of Polypharmacy Effects for Pain

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

FT576 in Subjects With Multiple Myeloma

Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

Pembro With Radiation With or Without Olaparib

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

MPC-004 for the Treatment of an Acute Gout Flare

Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)